The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study

Archive ouverte

Markousis‐mavrogenis, George | Tromp, Jasper | Ouwerkerk, Wouter | Devalaraja, Matt | Ankers, Stefan, D | Cleland, John, G | Dickstein, Kenneth | Filippatos, Gerasimos, S | Van Der Harst, Pim | Lang, Chim, C | Metra, Marco | Ng, Leong, L | Ponikowski, Piotr | Samani, Nilesh, J | Zannad, Faiez | Zwinderman, Aeilko, H | Hillege, Hans, L | Veldhuisen, Dirk, J | Kakkar, Rahul | Voors, Adriaan, A | Meer, Peter

Edité par CCSD ; European Society of Cardiology (Wiley) -

International audience. Aims: Inflammation is a central process in the pathophysiology of heart failure (HF), but trials targeting tumour necrosis factor (TNF)-α were largely unsuccessful. Interleukin (IL)-6 is an important inflammatory mediator and might constitute a potential pharmacologic target in HF. However, little is known regarding the association between IL-6 and clinical characteristics, outcomes and other inflammatory biomarkers in HF. We thus aimed to identify and characterize these associations.Methods and results: Interleukin-6 was measured in 2329 patients [89.4% with a left ventricular ejection fraction (LVEF) ≤ 40%] of the BIOSTAT-CHF cohort. The primary outcome was all-cause mortality and HF hospitalization during 2 years, with all-cause, cardiovascular (CV), and non-CV death as secondary outcomes. Approximately half (56%) of all included patients had plasma IL-6 values greater than the previously determined 95th percentile of normal values at baseline. Elevated N-terminal pro-brain natriuretic peptide, procalcitonin and hepcidin, younger age, TNF-α/IL-1-related biomarkers, or having iron deficiency, atrial fibrillation and LVEF > 40% independently predicted elevated IL-6 levels. IL-6 independently predicted the primary outcome [HR (95% confidence interval) per doubling: 1.16 (1.11-1.21), P < 0.001], all-cause mortality [1.22 (1.16-1.29), P < 0.001] and CV as well as non-CV mortality [1.16 (1.09-1.24), P < 0.001; 1.31 (1.18-1.45), P < 0.001], but did not improve discrimination in previously published risk models.Conclusions: In a large, heterogeneous cohort of HF patients, elevated IL-6 levels were found in more than 50% of patients and were associated with iron deficiency, reduced LVEF, atrial fibrillation and poorer clinical outcomes. These findings warrant further investigation of IL-6 as a potential therapeutic target in specific HF subpopulations.

Suggestions

Du même auteur

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF

Archive ouverte | Pagnesi, Matteo | CCSD

International audience. Aims: Few data regarding the prevalence and prognostic impact of mitral regurgitation (MR) in patients with worsening chronic or new-onset acute heart failure (HF) are available. We investiga...

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment

Archive ouverte | Nauta, Jan, F | CCSD

International audience. Aims: Heart failure is traditionally classified by left ventricular ejection fraction (LVEF), rather than by left ventricular (LV) geometry, with guideline-recommended therapies in heart fail...

Multi-omics analysis provides novel pathways related to progression of heart failure

Archive ouverte | Ouwerkerk, Wouter | CCSD

International audience

Chargement des enrichissements...